Vanda Pharmaceuticals Inc
VNDA4.520USD
+0.130+2.96%
終値 09/18, 16:00（ET）15分遅れの株価
267.04M時価総額
損失額直近12ヶ月PER
詳細情報 Vanda Pharmaceuticals Inc 企業名
Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).
企業情報
企業コードVNDA
会社名Vanda Pharmaceuticals Inc
上場日Apr 12, 2006
最高経営責任者「CEO」Dr. Mihael Hristos Polymeropoulos, M.D.
従業員数368
証券種類Ordinary Share
決算期末Apr 12
本社所在地Suite 300E
都市WASHINGTON
証券取引所NASDAQ Global Market Consolidated
国United States of America
郵便番号20037
電話番号12027343400
ウェブサイトhttps://www.vandapharma.com/
企業コードVNDA
上場日Apr 12, 2006
最高経営責任者「CEO」Dr. Mihael Hristos Polymeropoulos, M.D.
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Mihael Hristos Polymeropoulos, M.D.
Dr. Mihael Hristos Polymeropoulos, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
2.34M
+0.43%
Mr. Gunther Birznieks
Mr. Gunther Birznieks
Senior Vice President - Business Development
Senior Vice President - Business Development
411.63K
+73.26%
Mr. Kevin Patrick Moran
Mr. Kevin Patrick Moran
Chief Financial Officer, Senior Vice President, Treasurer
Chief Financial Officer, Senior Vice President, Treasurer
329.46K
+118.08%
Mr. Richard W. Dugan
Mr. Richard W. Dugan
Lead Independent Director
Lead Independent Director
177.45K
+50.09%
Dr. Tage Honore, Ph.D.
Dr. Tage Honore, Ph.D.
Independent Director
Independent Director
123.47K
+92.19%
Ms. Anne Sempowski Ward
Ms. Anne Sempowski Ward
Independent Director
Independent Director
119.07K
+98.97%
Dr. Stephen Ray Mitchell, M.D.
Dr. Stephen Ray Mitchell, M.D.
Independent Director
Independent Director
97.08K
+116.43%
Mr. Timothy I. Williams
Mr. Timothy I. Williams
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
--
--
Ms. Phaedra S. Chrousos
Ms. Phaedra S. Chrousos
Independent Director
Independent Director
--
--
Mr. Joakim (Kim) Wijkstrom
Mr. Joakim (Kim) Wijkstrom
Senior Vice President, Chief Marketing Officer
Senior Vice President, Chief Marketing Officer
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Mihael Hristos Polymeropoulos, M.D.
Dr. Mihael Hristos Polymeropoulos, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
2.34M
+0.43%
Mr. Gunther Birznieks
Mr. Gunther Birznieks
Senior Vice President - Business Development
Senior Vice President - Business Development
411.63K
+73.26%
Mr. Kevin Patrick Moran
Mr. Kevin Patrick Moran
Chief Financial Officer, Senior Vice President, Treasurer
Chief Financial Officer, Senior Vice President, Treasurer
329.46K
+118.08%
Mr. Richard W. Dugan
Mr. Richard W. Dugan
Lead Independent Director
Lead Independent Director
177.45K
+50.09%
Dr. Tage Honore, Ph.D.
Dr. Tage Honore, Ph.D.
Independent Director
Independent Director
123.47K
+92.19%
Ms. Anne Sempowski Ward
Ms. Anne Sempowski Ward
Independent Director
Independent Director
119.07K
+98.97%
収益内訳
通貨: USD更新時刻: Sun, Jul 6
通貨: USD更新時刻: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
事業別USD
会社名
収益
比率
Fanapt
23.55M
47.05%
Hetlioz
20.87M
41.71%
PONVORY
5.62M
11.24%
データなし
事業別
地域別
事業別USD
会社名
収益
比率
Fanapt
23.55M
47.05%
Hetlioz
20.87M
41.71%
PONVORY
5.62M
11.24%
株主
更新時刻: Fri, Aug 15
更新時刻: Fri, Aug 15
株主統計
種類
株主統計
株主統計
比率
BlackRock Institutional Trust Company, N.A.
10.13%
The Vanguard Group, Inc.
5.99%
Renaissance Technologies LLC
5.83%
Millennium Management LLC
5.28%
Dimensional Fund Advisors, L.P.
4.38%
他の
68.38%
株主統計
株主統計
比率
BlackRock Institutional Trust Company, N.A.
10.13%
The Vanguard Group, Inc.
5.99%
Renaissance Technologies LLC
5.83%
Millennium Management LLC
5.28%
Dimensional Fund Advisors, L.P.
4.38%
他の
68.38%
種類
株主統計
比率
Investment Advisor
27.77%
Investment Advisor/Hedge Fund
27.30%
Hedge Fund
19.35%
Individual Investor
7.19%
Research Firm
3.41%
Pension Fund
0.72%
Bank and Trust
0.20%
Sovereign Wealth Fund
0.19%
Venture Capital
0.05%
他の
13.82%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
417
50.75M
85.90%
-11.31M
2025Q1
426
48.51M
82.37%
-12.27M
2024Q4
444
46.48M
79.71%
-15.23M
2024Q3
446
47.42M
81.36%
-14.93M
2024Q2
445
46.99M
80.73%
-18.42M
2024Q1
434
53.50M
92.97%
-11.41M
2023Q4
445
55.38M
96.27%
-9.21M
2023Q3
446
56.79M
98.75%
-12.15M
2023Q2
434
60.42M
105.19%
-10.16M
2023Q1
437
62.04M
109.27%
-2.85M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
BlackRock Institutional Trust Company, N.A.
6.02M
10.21%
+16.86K
+0.28%
Mar 31, 2025
The Vanguard Group, Inc.
3.50M
5.93%
-11.00K
-0.31%
Mar 31, 2025
Renaissance Technologies LLC
3.57M
6.05%
-287.37K
-7.46%
Mar 31, 2025
Millennium Management LLC
3.12M
5.29%
+980.75K
+45.84%
Jun 27, 2025
Dimensional Fund Advisors, L.P.
2.54M
4.31%
+51.16K
+2.06%
Mar 31, 2025
BlackRock Financial Management, Inc.
2.15M
3.64%
+14.97K
+0.70%
Mar 31, 2025
Tang Capital Management, LLC
2.35M
3.99%
--
--
Mar 31, 2025
Polymeropoulos (Mihael Hristos)
2.33M
3.95%
+30.00K
+1.31%
May 21, 2025
Acadian Asset Management LLC
1.89M
3.2%
-12.95K
-0.68%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.61M
2.74%
+163.33K
+11.26%
Mar 31, 2025
詳細を見る
関連ETF
銘柄名
比率
データなし
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
